NIR-II imaging probe and methods of using the NIR-II imaging probe for dynamic in vivo tracking

US11951187B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11951187-B2
Application numberUS-202117179948-A
CountryUS
Kind codeB2
Filing dateFeb 19, 2021
Priority dateFeb 19, 2020
Publication dateApr 9, 2024
Grant dateApr 9, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The disclosure provides NIR-II imaging probes and methods of using the NIR-II imaging probes for dynamic in vivo tracking of cells, such as stem cells, or other substances. NIR-II imaging probes can include a biocompatible NIR-II dye molecule coupled to an organic, biocompatible protein carrier complex, including a carrier protein coupled to a cell-penetrating peptide.

First claim

Opening claim text (preview).

The invention claimed is: 1. An NIR-II optical imaging probe comprising: a biocompatible NIR-II dye molecule coupled to an organic, biocompatible protein carrier complex, the protein carrier complex comprising a carrier protein coupled to a cell-penetrating peptide (CPP), wherein the probe emits detectable NIR-II fluorescence and wherein the molar ratio of the NIR-II dye molecule to carrier protein to CPP is from about 0.5-1.5 NIR-II dye molecule to 0.5-1.5 carrier protein to 0.5-1.5 CPP. 2. The NIR-II optical imaging probe of claim 1 , wherein the carrier protein comprises a serum albumin protein. 3. The NIR-II optical imaging probe of claim 2 , wherein the serum albumin protein is selected from human serum albumin (HSA) molecule and bovine serum albumin (BSA) molecule. 4. The NIR-II optical imaging probe of claim 1 , wherein the CPP comprises trans-activator of transcription (Tat) peptide of HIV, or a derivative or segment thereof retaining cell membrane penetrating functionality. 5. The NIR-II optical imaging probe of claim 4 , wherein the Tat peptide comprises a peptide sequence having at least 75% sequence identity with SEQ ID NO: 1. 6. The NIR-II optical imaging probe of claim 1 , wherein the biocompatible NIR-II dye molecule is selected from the group consisting of: CH-4T, CH1055, carboxyl NIR-II dye molecules, NIR-II cyanine dye molecules, and combinations thereof. 7. The NIR-II optical imaging probe of claim 6 , wherein the biocompatible NIR-II dye molecule is CH-4T. 8. The NIR-II optical imaging probe of claim 1 , wherein the carrier protein is coupled to the CPP through a carbodiimide-mediated coupling reaction. 9. The NIR-II optical imaging probe of claim 1 , wherein the molar ratio of the NIR-II dye molecule to carrier protein to CPP is about 1 NIR-II dye molecule to 1 carrier protein to 1 CPP. 10. A cell including at least one NIR-II optical imaging probe of claim 1 . 11. The cell of claim 10 , wherein the cell is selected from the group consisting of: a stem cell, a pluripotent cell, an immune cell, a donor cell, and a cancer cell. 12. The cell of claim 10 , wherein the cell is a human stem cell. 13. A pharmaceutically acceptable imaging composition comprising: a plurality of NIR-II optical imaging probes of claim 1 or a plurality of target cells, wherein at least a portion of the target cells each include one or more of the NIR-II optical imaging probes of claim 1 ; and a pharmaceutically acceptable carrier. 14. The pharmaceutically acceptable imaging composition of claim 13 , wherein the composition comprises a plurality of target cells, wherein at least a portion of the target cells each include one or more of the NIR-II optical imaging probes of claim 1 and wherein the cells are selected from the group consisting of: stem cells, immune cells, and donor cells. 15. An imaging kit comprising: the pharmaceutically acceptable imaging composition of claim 13 , and instructions for administration of the pharmaceutically acceptable imaging composition to a patient and imaging of the patient.

Assignees

Inventors

Classifications

  • Peptides, proteins, polyamino acids · CPC title

  • the fluorescent group being a small organic molecule · CPC title

  • Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11951187B2 cover?
The disclosure provides NIR-II imaging probes and methods of using the NIR-II imaging probes for dynamic in vivo tracking of cells, such as stem cells, or other substances. NIR-II imaging probes can include a biocompatible NIR-II dye molecule coupled to an organic, biocompatible protein carrier complex, including a carrier protein coupled to a cell-penetrating peptide.
Who is the assignee on this patent?
Univ Leland Stanford Junior, The Board Of Trustees Of Leland Stanford Junior Univ
What technology area does this patent fall under?
Primary CPC classification A61K49/0056. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).